老年综合评估对接受抗癌治疗老年人不良事件风险的影响:系统综述与荟萃分析
该系统综述与荟萃分析纳入6项随机对照试验共2126名接受非手术抗癌治疗(主要为化疗)的老年人,评估老年综合评估(CGA)对治疗相关毒性的预防效果。结果显示CGA组3级及以上毒性发生率为51.7%,对照组为64.7%(RR=0.81,95%CI:0.7-0.94,P=0.005),且CGA与治疗期间剂量降低发生率更低相关(RR=0.73,P<0.00001),但在早期治疗中断、初始治疗强度降低、治疗延迟、住院及生存方面无显著差异。
要点
- CGA可降低接受非手术抗癌治疗老年人的3级及以上毒性风险(RR=0.81)。
- CGA与治疗期间剂量降低发生率更低相关(RR=0.73)。
- CGA对早期治疗中断、住院及生存无显著影响。
核心结论
- 在接收非手术抗癌治疗的老年人中,CGA可能与治疗相关毒性及剂量降低的发生率更低相关。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane图书馆从建库至2022年1月的随机对照试验。
- 共纳入6项随机对照试验,发表于2016至2021年,招募2126名参与者,中位年龄71-77岁,主要接受化疗。
主要发现
- CGA组3级及以上毒性发生率为51.7%,对照组为64.7%(RR=0.81,95%CI:0.7-0.94,P=0.005,I2=65%,证据确定性中等)。
- 早期治疗中断发生率无显著差异(RR=0.88,P=0.47;I2=63%,1408名参与者,证据确定性低)。
- 初始治疗强度降低发生率无显著差异(RR=0.99,P=0.94;I2=83%,2055名参与者,证据确定性低)。
- 治疗延迟发生率无显著差异(RR=1.06,P=0.77,I2=0%,309名参与者,证据确定性中等)。
- 住院发生率无显著差异(RR=0.86,P=0.39,I2=41%,914名参与者,证据确定性中等)。
关键数值与推荐
- 主要结局为采用常见不良事件术语标准(CTCAE)测量的毒性发生率。
- 次要结局包括治疗调整、早期治疗中断、无进展生存期、总生存期和住院。
临床怎么用
- 对接受非手术抗癌治疗的老年人,可考虑使用CGA以降低治疗相关毒性和剂量降低风险。
局限性
- 需要进一步大规模研究来支持本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: to assess the efficacy of comprehensive geriatric assessment (CGA) for preventing treatment-related toxicity in older people undergoing non-surgical cancer therapies. METHODS: MEDLINE, EMBASE and Cochrane library databases were searched from inception till January 2022 to identify randomised controlled trials (RCTs) on the incidence of toxicity measured by the Common Terminology Criteria for Adverse Events (primary outcome) and that of therapeutic modifications, early treatment discontinuation, progression-free survival, overall survival and hospitalisation (secondary outcomes). RESULTS: analysis of six RCTs published from 2016 to 2021 recruiting 2,126 participants (median age: 71-77) who received chemotherapy as the major therapeutic approach revealed 51.7% and 64.7% of Grade 3+ toxicity in the CGA and control (i.e. standard care) groups, respectively (RR = 0.81, 95% CI: 0.7-0.94, P = 0.005, I2 = 65%, certainty of evidence [COE]: moderate). There were no significant differences in the incidence of early treatment discontinuation (RR = 0.88, P = 0.47; I2 = 63%,1,408 participants, COE: low), initial reduction in treatment intensity (RR = 0.99, P = 0.94; I2 = 83%, 2055 participants, COE: low), treatment delay (RR = 1.06, P = 0.77, I2 = 0%, 309 participants, COE: moderate), hospitalisation (RR = 0.86, P = 0.39, I2 = 41%, 914 participants, COE: moderate), progression-free and overall survival with or without CGA. However, there was an association between CGA and a lower incidence of dose reduction during treatment (RR = 0.73, P < 0.00001, 956 participants, COE: moderate). CONCLUSIONS: our results demonstrated that comprehensive geriatric assessment may be associated with a lower incidence of treatment-related toxicity and dose reduction compared to standard care in older people receiving non-surgical cancer treatments. Further large-scale studies are warranted to support our findings.
引用
- Chuang MH, Chen JY, Tsai WW, et al. Impact of comprehensive geriatric assessment on the risk of adverse events in the older patients receiving anti-cancer therapy: a systematic review and meta-analysis. Age Ageing. 2022. PMID: 35776674. doi:10.1093/ageing/afac145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。